HAHesham Gaber Al-Inany

Hesham Gaber Al-Inany

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hesham Gaber Al-Inany has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Transrectal Ovum Pick up in Virgins: A Case Series Study

    by Hesham Gaber Al-Inany, Amal Shohayeb, Ahmed Shamel

    Objective : to evaluate the feasibility and safety of aspitating follicles for virgin seeking social oocyte cryopreservation through transrectal approach Setting : Tertiary referral center (Ganna IVF & Research center)Design: descriptive study over two years (2023-2025)Participants & Methods : All virgins coming for oocyte cryopreservation whether for social indications (mostly) or scheduled for chemotherapy were superstimulated by antagonist protocol and OPU was done after strict colon preparation through transrectal approach under heavy antibiotic coverage.Results: All cases were done smoothly without any complications and oocytes were retrieved successfully and only MII were frozen. Follow up showed no significant infection or subclinical infections. Cryopreservation of oocytes was done successfully and all cases were discharged without complicationsConclusion: Transrectal OPU is feasible and effective if strict precautions are taken. This is a suitable approach for virgins in Islamic countries to keep hymen integrity.Keywords: virgins, oocyte cryopreservation , Islamic countries


  • Open Access

    Could the Trustworthiness in RAndomized Controlled Trials (TRACT) checklist be trusted?

    by Hesham G Alinany, Ahmed M Sobh, Ahmed F Galal, Elnomrosy, Ahmed Y Rezk

    Randomized controlled trials (RCTs) are considered the gold standard study design in clinical effectiveness research, albeit some RCTs have been found to be fraudulent post-publication. The Trustworthiness in RAndomized Controlled Trials (TRACT) checklist examines RCT integrity through an assessment covering seven domains. While the authors claim that it can identify problematic trials, it has never been validated. A critical appraisal of the checklist highlights major failures in terms of health measurement methodology, including the arbitrary nature of items chosen. We applied the checklist to 16 RCTs coauthored by the checklist developer, and identified potential violations related to retrospective registration, ethical implications, authorship, methodology, implausible timeframes, zero participants to follow-up, implausible baseline characteristics, and excessive inter-group within trial as well as inter-trial similarities. In addition, we identified inconsistencies between the trials’ registration and data in the final published manuscripts. If we uncritically assume that the checklist is valid, then a formal institutional investigation into the trial portfolio its developer is warranted; especially targeting these 16 trials objectively shown to be problematic. The checklist should be considered as neither investigative nor conclusive of potential problems with RCTs until it is further refined and validated.

  • Top Cited Papers

    Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

    by Hesham G Al-Inany, Mohamed A Youssef, Reuben Olugbenga Ayeleke, Julie Brown, Wai Sun Lam, Frank J Broekmans

    Gonadotrophin-releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo-oestrogenic side-effects, flare-up, or long down-regulation period associated with agonists. The antagonists directly and rapidly inhibit gonadotrophin release within several hours through competitive binding to pituitary GnRH receptors. This property allows their use at any time during the follicular phase. Several different regimens have been described including multiple-dose fixed (0.25 mg daily from day six to seven of stimulation), multiple-dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single-dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill. Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS). Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens. This is an update of a Cochrane review first published in 2001, and previously updated in 2006 and 2011. To evaluate the effectiveness and safety of gonadotrophin-releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycles. We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (searched from inception to May 2015), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library, inception to 28 April 2015), Ovid MEDLINE (1966 to 28 April 2015), EMBASE (1980 to 28 April 2015), PsycINFO (1806 to 28 April 2015), CINAHL (to 28 April 2015) and trial registers to 28 April 2015, and handsearched bibliographies of relevant publications and reviews, and abstracts of major scientific meetings, for example the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM). We contacted the authors of eligible studies for missing or unpublished data. The evidence is current to 28 April 2015. Two review authors independently screened the relevant citations for randomised controlled trials (RCTs) comparing different GnRH agonist versus GnRH antagonist protocols in women undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). Two review authors independently assessed trial eligibility and risk of bias, and extracted the data. The primary review outcomes were live birth and ovarian hyperstimulation syndrome (OHSS). Other adverse effects (miscarriage and cycle cancellation) were secondary outcomes. We combined data to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs). Statistical heterogeneity was assessed using the I2 statistic. We assessed the overall quality of the evidence for each comparison using GRADE methods. We included 73 RCTs, with 12,212 participants, comparing GnRH antagonist to long-course GnRH agonist protocols. The quality of the evidence was moderate: limitations were poor reporting of study methods. Live birth There was no conclusive evidence of a difference in live birth rate between GnRH antagonist and long course GnRH agonist (OR 1.02, 95% CI 0.85 to 1.23; 12 RCTs, n = 2303, I2= 27%, moderate quality evidence). The evidence suggested that if the chance of live birth following GnRH agonist is assumed to be 29%, the chance following GnRH antagonist would be between 25% and 33%. OHSS GnRH antagonist was associated with lower incidence of any grade of OHSS than GnRH agonist (OR 0.61, 95% C 0.51 to 0.72; 36 RCTs, n = 7944, I2 = 31%, moderate quality evidence). The evidence suggested that if the risk of OHSS following GnRH agonist is assumed to be 11%, the risk following GnRH antagonist would be between 6% and 9%. Other adverse effects There was no evidence of a difference in miscarriage rate per woman randomised between GnRH antagonist group and GnRH agonist group (OR 1.04, 95% CI 0.82 to 1.30; 33 RCTs, n = 7022, I2 = 0%, moderate quality evidence). With respect to cycle cancellation, GnRH antagonist was associated with a lower incidence of cycle cancellation due to high risk of OHSS (OR 0.47, 95% CI 0.32 to 0.69; 19 RCTs, n = 4256, I2 = 0%). However cycle cancellation due to poor ovarian response was higher in women who received GnRH antagonist than those who were treated with GnRH agonist (OR 1.32, 95% CI 1.06 to 1.65; 25 RCTs, n = 5230, I2 = 68%; moderate quality evidence). There is moderate quality evidence that the use of GnRH antagonist compared with long-course GnRH agonist protocols is associated with a substantial reduction in OHSS without reducing the likelihood of achieving live birth.


  • Epidural analgesia in the latent phase of labor and its effects on labor and fetal outcomes

    by Heba Wageih, Osama Hosny, Hany Hassan, Hesham Al-Inany

    Objective To evaluate the effect of epidural analgesia (EA) on the progress of labor when applied during the latent phase and whether or not the mode of delivery will be affected. Design Randomized-controlled trial. Setting Kasr Al Ainy Hospital. Participants and methods Pregnant women in labor were divided into two groups: group A included women in the latent phase of labor and group B included women in the active phase of labor. EA was administered for all cases and follow-up for maternal and fetal outcomes was carried out. Results There were no significant differences between any of the parameters tested, except the rate of cervical dilatation. There were no adverse effects on the fetus in either group. Conclusion EA in the latent phase of labor does not seem to differ from its application in the active phase in terms of progress of labor or fetal outcome.

  • Open Access

    Changing Attitudes in Ovarian Stimulation

    by Hesham Al-Inany, Amr Wahba, Panagiotis Peitsidis


  • Are all human-derived follicle-stimulating hormone products the same? A systematic review and meta-analysis using direct and adjusted indirect analyses, to determine whether Fostimon®is more efficient than Metrodin-HP®

    by Hesham G. Al-Inany, Ahmed M. Abou-Setta

    Background. Randomized trials (RCTs) and systematic reviews have challenged the claim for superiority of recombinant follicle-stimulating hormone (recFSH) compared with human-derived FSH (hFSH). Even so, much of the evidence comes from unavailable products. If the efficacy of the currently available Fostimon® is superior, the off-market Metrodin-HP®, then data from the latter should not be used, gauge of the former. Methods. Electronic/hand searches were performed to identify RCTs comparing Fostimon® vs. Metrodin-HP® or either product with recFSH. Primary outcomes were live-birth rate (LBR), ongoing pregnancy rate (OPR), and OPR/LBR. Secondary outcomes were clinical pregnancy rate (CPR), multiple pregnancy rate (MPR), ovarian hyperstimulation syndrome (OHSS), abortion rates, and cycle demographics. Data were extracted, allowed for an intention-to-treat analysis, and meta-analyzed using combined direct/adjusted indirect methods. Results. Twenty-two RCTs met the inclusion criteria: Fostimon® vs. Metrodin-HP® (n = 2); Fostimon® vs. recFSH (n = 8); and Metrodin-HP® vs. recFSH (n = 12). LBR (odds ratio = 1.72; 95% confidence interval = 1.05–2.80), OPR/LBR, and CPR were all significantly higher favoring Fostimon®. OPR, MPR, OHSS, and miscarriage rates were not significantly different. Pooled results for cycle demographics were not reported due to high heterogeneity. Conclusions. Fostimon® is superior to Metrodin-HP® regarding clinical outcomes. Therefore, care should be taken not to assume that all hFSH products have the same efficacy.


  • Gonadotrophin-releasing hormone antagonists for assisted reproductive technology

    by Hesham G Al-Inany, Mohamed Afm Youssef, Mohamed Aboulghar, Frank J Broekmans, Monique D. Sterrenburg, Janine G Smit, Ahmed M Abou-Setta

    Background Gonadotrophin‐releasing hormone (GnRH) antagonists can be used to prevent a luteinizing hormone (LH) surge during controlled ovarian hyperstimulation (COH) without the hypo‐estrogenic side‐effects, flare‐up, or long down‐regulation period associated with agonists. The antagonists directly and rapidly inhibit gonadotropin release within several hours through competitive binding to pituitary GnRH receptors. This property allows their use at any time during the follicular phase. Several different regimes have been described including multiple‐dose fixed (0.25 mg daily from day six to seven of stimulation), multiple‐dose flexible (0.25 mg daily when leading follicle is 14 to 15 mm), and single‐dose (single administration of 3 mg on day 7 to 8 of stimulation) protocols, with or without the addition of an oral contraceptive pill. Further, women receiving antagonists have been shown to have a lower incidence of ovarian hyperstimulation syndrome (OHSS). Assuming comparable clinical outcomes for the antagonist and agonist protocols, these benefits would justify a change from the standard long agonist protocol to antagonist regimens. This is an update of a Cochrane review first published in 2001, and previously updated in 2006. Objectives To evaluate the effectiveness and safety of gonadotrophin‐releasing hormone (GnRH) antagonists compared with the standard long protocol of GnRH agonists for controlled ovarian hyperstimulation in assisted conception cycle Search methods We performed electronic searches of major databases, for example Cochrane Menstrual Disorders and Subfertility Group Specialised Register, CENTRAL, MEDLINE, EMBASE (from 1987 to April 2010); and handsearched bibliographies of relevant publications and reviews, and abstracts of major scientific meetings, for example the European Society of Human Reproduction and Embryology (ESHRE) and American Society for Reproductive Medicine (ASRM). Selection criteria Two review authors independently screened the relevant citations for randomised controlled trials (RCTs) comparing different agonist versus antagonist protocols in women undergoing IVF or ICSI. Data collection and analysis Two review authors independently assessed trial risk of bias and extracted data. If relevant data were missing or unclear, the authors were contacted for clarification. Main results Forty‐five RCTs (n = 7511) comparing the antagonist to the long agonist protocols fulfilled the inclusion criteria. There was no evidence of a statistically significant difference in rates of live‐births (9 RCTs; odds ratio (OR) 0.86, 95% CI 0.69 to 1.08). There was a statistically significant lower incidence of OHSS in the GnRH antagonist group (29 RCTs; OR 0.43, 95% CI 0.33 to 0.57). Authors' conclusions The use of antagonist compared with long GnRH agonist protocols was associated with a large reduction in OHSS and there was no evidence of a difference in live‐birth rates.


  • Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles

    by Mohamed Afm Youssef, Hesham G Al-Inany, Mohamed Aboulghar, Ragaa Mansour, Ahmed M Abou-Setta

    For the last few decades urinary human chorionic gonadotrophin (hCG) has been used to induce final oocyte maturation triggering in in vitro fertilization (IVF) and intra‐cytoplasmic sperm injection (ICSI) cycles. Recombinant technology has allowed the production of two drugs that can be used for the same purpose, to mimic the endogenous luteinizing hormone (LH) surge. This allows commercial production to be adjusted according to market requirements; the removal of all urinary contaminants; and the safe subcutaneous administration of a compound with less batch‐to‐batch variation. However, prior to a change in practice the effectiveness of the recombinant drugs should be known compared to the currently used urinary human chorionic gonadotrophin (uhCG). To assess the efficacy and safety of subcutaneous recombinant hCG (rhCG) and high dose recombinant LH (rLH) compared with intramuscular uhCG for inducing final oocyte maturation triggering in IVF and ICSI cycles. We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (January 2010), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010), MEDLINE (1966 to January 2010) and EMBASE (1980 to January 2010). Two review authors independently scanned titles and abstracts and selected those that appeared relevant for collection of the full paper. Only truly randomised controlled trials comparing rhCG and rLH with urinary hCG for final oocyte maturation triggering in IVF and ICSI cycles for treatment of infertility in normo‐gonadotropic women were included. Assessment for inclusion or exclusion, quality assessment and data extraction were performed independently by two authors. Discrepancies were discussed in the presence of a third author and consensus reached. Quality assessment included method of randomisation, allocation concealment, blinding of participants and assessors, reporting of a power calculation and intention‐to‐treat analysis. Fourteen RCTs (n = 2306) were identified; 11 compared rhCG with uhCG and three compared rhLH with uhCG. There was no evidence of a statistically significant difference between rhCG and uhCG regarding the ongoing pregnancy or live birth rate (6 RCTs: OR 1.04, 95% CI 0.79 to 1.37; P = 0.83, I2 = 0%). There was no significant difference in the incidence of ovarian hyperstimulation syndrome (OHSS) between rhCG and uhCG (3 RCTs: OR 1.5, 95% CI 0.37 to 4.1; P = 0.37, I2 = 0%). There was no evidence of statistically significant difference between rhLH and uhCG regarding the ongoing pregnancy or live birth rate (OR 0.94, 95% CI 0.50 to 1.76) and incidence of OHSS (OR 0.82, 95% CI 0.39 to 1.69). These results leave open the possibility of strong differences in favour of either treatment for both ongoing pregnancy and OHSS. We conclude that there is no evidence of difference between rhCG or rhLH and uhCG in achieving final follicular maturation in IVF, with equivalent pregnancy rates and OHSS incidence. According to these findings uHCG is still the best choice for final oocyte maturation triggering in IVF and ICSI treatment cycles. 對於人工受孕當中的誘導排卵而言,重組型的與泌尿型的人類絨毛膜性腺激素之比較 過去的這幾十年來,泌尿型的人類的絨毛膜性腺激素已經被用來誘導最後的卵泡成熟,並且被用在人工受孕當中以啟動排卵。有2種藥物就是因為重組技術而被製造出來,而它們都可以被用在相同的目的上:模擬內生性的促黃體生成素(LH)高峰。這樣的作法將可以達到商業化的量產,並且能夠根據市場上的需要來進行調整。除此之外,所有泌尿道的汙染物也可被清理乾淨。因此,這樣就可以讓某種化合物安全地皮下注射,而且每批次與每批次之間的變數也會比較少。然而,在實務方面進行某種改變之前,而且跟這些目前已經在使用的泌尿型人類絨毛膜性腺激素比較起來,應該要了解這些重組型藥物的功效。 對於誘導最終的卵母細胞成熟與啟動排卵而言,跟採取肌肉注射方式的泌尿道型人類絨毛膜性腺激素比較起來,要評估皮下注射的重組型人類絨毛膜性腺激素與高劑量的人類促黃體生成素之安全性與功效。 我們搜尋 Cochrane Menstrual Disorders以及Subfertility Group trials register (27 August 2003)、 Cochrane Central Register of Controlled Trials (CENTRAL on Cochrane Library, issue 4, 2003)、 MEDLINE (1966年–2004年2月) 以及 EMBASE (1980年–2004年2月)。搜尋時不作語言限制。並搜尋被排除及被納入的試驗以及重要研討會的摘要的書目以找出額外試驗。另外還聯絡作者即藥廠乙獲得遺漏以及未發表的數據。 有2位審稿者獨立地掃瞄過標題與摘要,並且挑選出那些看起來跟整篇文章之收集有關的對象。對於正常促性腺激素型的婦女們進行不孕症治療時,針對在人工受孕期間為了啟動排卵而言,只有真實地經過隨機化的對照試驗,並且將重組型人類絨毛膜性腺激素或是高劑量的重組型促黃體生成素與泌尿道型的人類絨毛膜性腺激素進行過比較,才會被收集在內。 收集/排除的評估、品質的評估,以及資料的擷取,都是由2位以上的審稿者獨立完成。關於出現意見不合的情況,則會在某位第3審稿者在場的情形下加以討論,然後達成某種共識。品質的評估包含了隨機化的方法、隱藏分配工作、讓參與者以及評估者採取盲法、對於某種力度計算的報告、意向治療的分析,以及中途停止的處理方法。資料擷取的部分包括了參與者的特徵、介入行為與對照的過程,以及結果。 當中共確認了7份隨機對照試驗,有4份比較了重組型的人類絨毛膜性腺激素與泌尿道型的人類絨毛膜性腺激素,而有3份則比較了重組型的人類促黃體生成素與泌尿道型的人類促黃體生成素。若是就持續懷孕/產下活胎的比率(OR 0.98,95% CI 0.69到1.39)、懷孕的比率、流產,或發生卵巢過度刺激症候群的情況來看,在重組型的人類絨毛膜性腺激素相較於泌尿道型的人類絨毛膜性腺激素之間,並沒有統計學上的顯著差異。若是就正在持續當中的懷孕/產下活胎的比率(OR 0.94,95% CI 0.50到1.76)、懷孕的比率、流產,或發生卵巢過度刺激症候群的情況來看,在重組型的人類促黃體生成素相較於泌尿道型的人類絨毛膜性腺激素之間,並沒有統計學上的顯著差異。重組型的人類促黃體生成素之製造商已經決定,不會再繼續開發這種產品。重組型的人類絨毛膜性腺激素會使得局部位置發生反應的情況以及其他種次要的不良影響都變得比較少(OR 0.47,95% CI 0.32到0.70)。 對於誘導最終的卵泡成熟而言,在泌尿道型的與重組型的性腺激素之間,就臨床結果方面來看,並沒有證據能夠顯示出差異。當我們在選擇性腺激素的類型時,應該要將更多的因素列入考量,包括了安全性、費用,以及藥物的可用性。 Comparaison entre la gonadotrophine chorionique humaine recombinante et celle provenant de l'urine pour le déclenchement de la maturation finale des ovocytes dans les cycles de FIV et d'IICS Depuis quelques décennies, la gonadotrophine chorionique humaine (hCG) provenant de l'urine est utilisée pour induire le déclenchement de la maturation finale des ovocytes dans les cycles de fécondation in vitro (FIV) et d'injection intracytoplasmique de spermatozoïdes (IICS). La technologie recombinante a permis la production de deux médicaments qui peuvent être utilisés dans le même but, pour imiter la poussée d'hormone lutéinisante (LH) endogène. Cela permet d'ajuster la production commerciale en fonction des besoins du marché, l'élimination de la totalité des contaminants présents dans l'urine, et l'administration d'un composé par voie sous‐cutanée en toute sécurité et avec une moindre variation entre les différents lots. Cependant, avant de modifier la pratique, l'efficacité des médicaments recombinants doit être connue par rapport à celle de la gonadotrophine chorionique humaine provenant de l'urine (uhCG) actuellement utilisée. Afin d'évaluer l’efficacité et l’innocuité de l'hCG recombinante (rhCG) sous‐cutanée et de la LH recombinante (rLH) à forte dose par rapport à l'uhCG intramusculaire dans l'induction du déclenchement de la maturation finale des ovocytes dans les cycles de FIV et d'IICS, nous avons effectué des recherches dans le registre des essais du groupe Cochrane sur les troubles menstruels et de la fertilité (janvier 2010), le registre Cochrane des essais contrôlés (CENTRAL) (The Cochrane Library 2010), MEDLINE (de 1966 à janvier 2010) et EMBASE (de 1980 à janvier 2010). Deux auteurs de la revue ont indépendamment analysé les titres et les résumés et sélectionné ceux qui paraissaient pertinents pour la collecte de l'article complet. Seuls les essais contrôlés véritablement randomisés comparant la rhCG et la rLH à l'hCG provenant de l'urine pour le déclenchement de la maturation finale des ovocytes dans les cycles de FIV et d'IICS dans le traitement de l'infertilité chez les femmes normo‐gonadotropes ont été inclus. L'évaluation en vue de l'inclusion ou de l'exclusion, l’évaluation de la qualité et l'extraction des données ont été réalisées de façon indépendante par deux auteurs. Les divergences ont fait l'objet de discussions en présence d'un troisième auteur et un consensus a été atteint. L'évaluation de la qualité comprenait la méthode de randomisation, l'assignation secrète, la mise en aveugle des participants et des évaluateurs, l'indication d'un calcul de puissance et l'analyse en intention de traiter. Quatorze ECR (n = 2 306) ont été identifiés ; 11 comparaient la rhCG à l'uhCG et trois comparaient la rhLH à l'uhCG. Il n'a été observé aucune preuve d'une différence statistiquement significative entre la rhCG et l'uhCG en matière de taux de grossesses en cours ou de naissances vivantes (6 ECR : RC 1,04, IC à 95 % 0,79 à 1,37 , P = 0,83, I2 = 0 %). Il n'y avait pas de différence significative en termes d'incidence du syndrome d'hyperstimulation ovarienne (SHO) entre la rhCG et l'uhCG (3 ECR : RC 1,5, IC à 95 % 0,37 à 4,1 ; P = 0,37, I2 = 0 %). Aucune différence statistiquement significative n'a été observée entre la rhLH et l'uhCG en matière de taux de grossesses en cours ou de naissances vivantes (RC 0,94, IC à 95 % 0,50 à 1,76) et d'incidence du SHO (RC 0,82, IC à 95 % 0,39 à 1,69). Ces résultats laissent ouverte la possibilité de fortes différences en faveur de l'un ou l'autre traitement aussi bien pour les grossesses en cours que pour le SHO. Nous concluons qu'il n'existe aucune preuve indiquant une différence entre la rhCG ou la rhLH et l'uhCG dans l'obtention d'une maturation folliculaire finale dans la FIV, les taux de grossesse et l'incidence du SHO étant équivalents. D'après ces données, l'uHCG reste le meilleur choix pour le déclenchement de la maturation finale des ovocytes dans les cycles de traitement de FIV et d'IICS.


  • Open Access

    GnRH antagonists are safer than agonists: an update of a Cochrane review

    by Hesham G. Al-Inany, Mohamed A.F.M. Youssef, Mohamed Aboulghar, Frank Broekmans, Monique Sterrenburg, Janine Smit, Ahmed M. Abou-Setta

    GnRH agonists or antagonists can be used to prevent LH surges during ovarian stimulation for assisted reproduction. GnRH agonists down-regulate GnRH pituitary receptors. GnRH antagonists directly and rapidly inhibit gonadotrophin release. In a 2006 systematic review involving 29 trials, the average clinical pregnancy rate was 4.7% lower with GnRH antagonist treatment and the incidence of ovarian hyperstimulation syndrome (OHSS) was 2% lower compared with GnRH agonist treatment ( Al-Inany et al., 2006). The current update includes 45 trials which addressed live birth or ongoing pregnancy rate (OPR) in GnRH antagonist and GnRH agonist protocols among women undergoing assisted reproduction treatment ( Youssef et al., 2011).


  • The effectiveness of clomiphene citrate in LH surge suppression in women undergoing IUI: a randomized controlled trial

    by Hesham Al-Inany, Hamdy Azab, Waleed El-Khayat, Adel Nada, Eman El-Khattan, Ahmed M. Abou-Setta